目的 观察替格瑞洛治疗经皮冠状动脉介入(PCI)术后急性冠脉综合征(ACS)患者，对患者动脉炎性反应及血小板参 数的影响。方法 选取2015年10月至2017年10月我院收治的83例接受PCI术的ACS患者为对象，按照术后治疗方法的 不同分为实验组和对照组，实验组42例术后实施替格瑞洛治疗，对照组41例术后实施氯吡格雷治疗，对比两组术后 24h和药物治疗三个月后超敏C反应蛋白(hs-CRP)、白介素6(IL-6)、可溶性白细胞分化抗原40配体(sCD40L)、血小 板计数(PLT)、P2Y12反应单位(PRU)水平的改变和药物的不良反应率。结果 治疗前两组的hs-CRP、IL-6、sCD40L、 PLT、PRU水平相较均无明显差异(P＞0.05)，治疗后实验组的hs-CRP、IL-6、sCD40L、PLT、PRU水平和不良反应率 均明显低于照组(P＜0.05)。结论 替格瑞洛治疗PCI术后ACS患者，能有效减少患者的动脉炎性反应，降低患者体内 PLT、PRU水平，且不良反应发生率小，有一定的临床推广价值。

Objective To observe the effect of tigerrillo on arterial inflammatory response and platelet parameters in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). Methods 83 ACS patients who received PCI in our hospital from October 2015 to October 2017 were selected as objects, which were divided into experimental group and control group according to different postoperative treatment methods. 42 patients in the experimental group were treated with tigerrillo after surgery, and 41 patients in the control group were treated with clopidogrel after surgery. Changes in hypersensitive C response protein (hs-crp), interleukin 6(il-6), soluble leukocyte differentiation antigen 40 ligand (sCD40L), platelet count (PLT), P2Y12 response unit (PRU) levels and adverse drug response rates were compared between the two groups 24 hours after surgery and three months after drug treatment. Results The hs-crp, il-6, sCD40L, PLT and PRU levels of the two groups before treatment showed no significant difference (P>0.05), and the hs-crp, il-6, sCD40L, PLT, PRU levels and adverse reaction rates of the experimental group after treatment were significantly lower than those of the control group (P<0.05). Conclusion The treatment of ACS patients after PCI by tigerrillo can effectively reduce the arterial inflammatory reaction of patients, reduce the level of PLT and PRU in patients, and the incidence of adverse reactions is small, which has certain clinical value.